To deepen our understanding of the role of UBE2J1-loss in antiandrogen resistance, we examined two metastatic Castration Resistant Prostate Cancer (mCRPC) patient cohorts: the Stand Up to Cancer (SU2C) and Alumkal 2020 cohorts [22, 23, 39]. Here, UBE2J1 is linked to cancer.